Cart
sales@molnova.com
(20R)-Ginsenoside Rh1
CAS No. 80952-71-2
(20R)-Ginsenoside Rh1( —— )
Catalog No. M19132 CAS No. 80952-71-2
20S, 20R ginsenoside-Rh1 can inhibit the thrombin-induced conversion of fibrinogen to fibrin.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 56 | In Stock |
|
| 5MG | 35 | In Stock |
|
| 10MG | 57 | In Stock |
|
| 25MG | 103 | In Stock |
|
| 50MG | 151 | In Stock |
|
| 100MG | 221 | In Stock |
|
| 200MG | 331 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name(20R)-Ginsenoside Rh1
-
NoteResearch use only, not for human use.
-
Brief Description20S, 20R ginsenoside-Rh1 can inhibit the thrombin-induced conversion of fibrinogen to fibrin.
-
Description20S, 20R ginsenoside-Rh1 can inhibit the thrombin-induced conversion of fibrinogen to fibrin.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number80952-71-2
-
Formula Weight638.9
-
Molecular FormulaC36H62O9
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (156.53 mM)
-
SMILESO1[C@H]([C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O)O[C@@H]1[C@H]2C([C@H](CC[C@@]2([C@@H]2[C@@](C1)([C@@]1(CC[C@@H]([C@H]1[C@@H](C2)O)[C@@](C)(CCC=C(C)C)O)C)C)C)O)(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yu HS,et al. [Chemical constituents from processed rhizomes of Panax notoginseng]. Zhongguo Zhong Yao Za Zhi. 2013 Nov;38(22):3910-7.
molnova catalog
related products
-
Esculentoside C
Esculentoside C exerts proinflammatory effects synergistically, it can induce inflammatory stimulation.
-
D-F07
D-F07 is a novel fluorescent IRE-1 RNase inhibitor and a tricyclic chromone with potential anticancer activity.
-
STS-E412
STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.
